NCT03496584 (PomSkin) is a NA clinical trial of Pomegranate Juice in Erythema, sponsored by University of California, Los Angeles.

Who is sponsoring NCT03496584?

NCT03496584 is sponsored by University of California, Los Angeles.

What drugs are being tested in NCT03496584?

Interventions in NCT03496584: Pomegranate Juice, Placebo Juice.

What condition does NCT03496584 study?

NCT03496584 studies Erythema, Inflammation.

Is NCT03496584 still recruiting?

NCT03496584 is currently terminated. Last updated 19 April 2021.

Last reviewed 2021-04-19 · How we verify

NCT03496584: PomSkin

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Phytonutrients on Vascular Health and Skin in Obese Males

Terminated NA Last updated 19 April 2021

What this trial tests

NA trial testing Pomegranate Juice in Erythema in 35 participants. Terminated before completion.

Timeline

29 March 2018

Primary endpoint
28 February 2021

28 February 2021

Quick facts

Lead sponsor	University of California, Los Angeles
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	35
Start date	29 March 2018
Primary completion	28 February 2021
Estimated completion	28 February 2021
Sites	1 location across United States

Drugs / interventions tested

Pomegranate Juice
Placebo Juice — full drug profile →

Conditions studied

Erythema — all drugs for Erythema →
Inflammation — all drugs for Inflammation →

Sponsor

University of California, Los Angeles

Who can join

Adults 18 to 65, male only, with Erythema or Inflammation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will determine the effects of beneficial compounds of plant foods, such as pomegranate on cardiovascular health, skin inflammation and aging. This will be tested by asking healthy males to eat a high fat ground beef patty with 8oz. pomegranate juice or 8oz placebo (a study product that looks like pomegranate juice, but contains no active ingredients) and then measuring blood vessel dilation (endothelial function) by blood flow. The investigators also will measure the amount of Nitric Oxide (NO) in blood and urine samples and sugar and insulin in blood. In addition, a Cutometer, a device that measures the elasticity of the skin, will be used to obtain measurements of skin inflammation and aging. Healthy men have been chosen for this study because eating high fat hamburger patties can easily mimic in them the condition that causes atherosclerosis. The results from this study may help to explain how high fat foods can be harmful to the body and how beneficial plant foods can have on cardiovascular function and the skin.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Pomegranate Juice

Trials testing the same drug.

NCT04985630 — The Mitopure Challenge to Detect Levels of Urolithin A in Dried Blood Spots · NA · recruiting
NCT04596254 — Detection of Gut Metabolites in Mother's Milk Following Juice Intake · NA · completed
NCT04160312 — Mitopure™ (Proprietary Urolithin A) Bioavailability in Healthy Adults · NA · completed
NCT04341961 — Effect of Pomegranate Juice Consumption on the Health of Mothers and Infants During Breastfeeding · NA · completed
NCT03713164 — The Effects of Ellagic Acid From Pomegranate Juice vs. Pure Ellagic Acid on Healthy Male Subjects · NA · completed

Other recruiting trials for Erythema

Currently open trials in the same condition.

NCT07474883 — Efficacy of 0.5% Topical Timolol Eye Drops in the Treatment of Post-Inflammatory Erythema Following Acne Vulgaris · EARLY_PHASE1 · recruiting
NCT02876107 — Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer · Phase 2 · active not recruiting
NCT02411656 — Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative B · Phase 2 · active not recruiting

Other University of California, Los Angeles trials

Trials by the same sponsor.

NCT04846517 — rTMS for Aneroxia Nervosa in Youth · NA · not yet recruiting
NCT06701760 — Sodium Lactate in Severe TBI · Phase 2 · not yet recruiting
NCT04996667 — Effect of iNO in Patients With Submassive and Massive PE · Phase 2 · withdrawn
NCT05067387 — Evaluation of Oral THC and CBD in Men and Women · Phase 1 · not yet recruiting
NCT07534696 — Evaluation of Non-Invasive Pelvic Floor Neuromuscular Stimulation for Urinary Incontinence After Prostatectomy · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03496584 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, Los Angeles
Last refreshed: 19 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03496584.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing